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Abstract
 
Heat shock proteins (HSPs) derived from tumors or virally infected cells can stimulate antigen-
 
specific CD8
 
1
 
 T cell responses in vitro
 
 
 
and in vivo. Although this antigenicity is known to arise
from HSP-associated peptides presented to the immune system by major histocompatibility
complex (MHC) class I molecules, the cell biology underlying this presentation process remains
poorly understood. Here we show that HSP 70 binds to the surface of antigen presenting cells
by a mechanism with the characteristics of a saturable receptor system. After this membrane in-
teraction, processing and MHC class I presentation of the HSP-associated antigen can occur via
either a cytosolic (transporter associated with antigen processing [TAP] and proteasome–depen-
dent) or an endosomal (TAP and proteasome–independent) route, with the preferred pathway
determined by the sequence context of the optimal antigenic peptide within the HSP-associ-
ated material. These findings not only characterize two highly efficient, specific pathways lead-
ing to the conversion of HSP-associated antigens into ligands for CD8
 
1
 
 T cells, they also imply
the existence of a mechanism for receptor-facilitated transmembrane transport of HSP or HSP-
associated ligands from the plasma membrane or lumen of endosomes into the cytosol.
Key words: immunology • vaccines • macrophages • T cells • peptides
 
Introduction
 
Activation of the T cell limb of the adaptive immune sys-
tem involves the recognition of small ligands bound to
MHC or MHC-like proteins on plasma membranes. This
antigen presentation paradigm is best understood for pep-
tides associated with MHC class I or class II molecules, with
a large body of work having defined two distinct pathways
by which protein antigens are converted to shorter frag-
ments occupying the polymorphic binding domains of
these MHC glycoproteins (1). For MHC class I molecules,
peptides are mainly created by the action of proteasomal
enzymes on proteins present in the cytosol. These peptides
are then transported by the transporter associated with anti-
 
gen processing (TAP)
 
1
 
 dimer through the membrane of the
endoplasmic reticulum (ER), after which they are bound to
 
nascent MHC class I heavy chain–
 
b
 
2-microglobulin com-
plexes within the ER lumen (2). The occupied MHC mol-
ecules then pass through the secretory pathway to the cell
 
surface where they can interact with the receptors of CD8
 
1
 
T cells. MHC class II molecules instead interact primarily with
large polypeptides within various endosomal compartments
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(3–5), after which exopeptidases remove the unprotected
segments of the antigen outside of the MHC molecule
binding groove (6, 7). The resulting MHC class II–peptide
complexes are then exported to the plasma membrane for
recognition by CD4
 
1
 
 T cells.
Heat shock proteins (HSPs) are highly conserved pep-
tide-binding molecules that control the folding of proteins
and prevent their aggregation (8). The same peptide-bind-
ing capacity appears to allow HSPs to acquire proteinaceous
antigenic material within cells, and when administered ex-
ogenously, to induce priming of CD8
 
1
 
 T lymphocytes in
vivo
 
 
 
(9–13). This property suggests that there is efficient
transfer of antigen from HSPs to MHC class I molecules
under these conditions. Such transfer is surprising both be-
cause peptide loading of MHC class I molecules typically
involves a cytosol to ER route, and because while we un-
derstand the role of several well-defined receptor systems in
facilitating MHC class II–peptide presentation (14–18), lit-
tle is known about any specific pathways for capture and
delivery of exogenous antigens to (intracellular) MHC class
I molecules. In circumstances other than those known to
involve HSP (19–22), MHC class I presentation of peptides
derived from exogenous protein sources has been reported
and ascribed to either endosomal degradation of particulate
antigens, followed by “regurgitation” of the derived pep-
tides for loading of surface class I molecules (23), or to de-
livery of antigens from endosomes and/or phagosomes into
the cytosol by an unknown route (24–27). The relative
contribution of either of these proposed pathways to pre-
sentation of HSP-associated antigen has not been deter-
mined, nor is much known about the cell biology of such
exogenous pathways for MHC class I–peptide acquisition.
Several groups have recently reported that various HSP
molecules show cell surface binding and/or cellular uptake
that in some (28, 29) but not other (30) cases has the char-
acteristics expected of a saturable receptor system. How-
ever, these studies did not link these binding events to
functional antigen presentation, or address by what route
the antigen in the bound HSP is converted into peptides
associated with MHC class I molecules. Given other studies
showing active signaling by HSP for induction of cytokine
secretion by various cell types (31), it was possible that the
binding reported in these earlier investigations was related
to this functional stimulation and not necessarily to antigen
presentation. Here, we analyze HSP delivery of antigenic
material to MHC class I molecules using both functional
and morphologic methods. Our data reveal that saturable
uptake of the complexes, apparently through interaction
with one or more surface receptors, is important for deliv-
ering HSP-associated antigen to the cell for processing via
either an endosomal or a cytosolic route. Which processing
pathway is preferred appears to depend on the sequence
context of the antigenic peptide bound to the HSP. The
evidence presented here for proteasome-dependent pro-
cessing of HSP-derived material also implies the existence
of an uncharacterized mechanism for transport of HSP
complexes, or their cargo, across plasma or endosomal
membranes into the cytosol.
 
Materials and Methods
 
Cells.
 
Macrophages were collected by peritoneal lavage 6 d
after injection of 1 ml of thioglycollate into C57BL/6 or (C3H 
 
3
 
C57BL/6)F1 mice (The Jackson Laboratory). B3Z is a CD8
 
1
 
 T
cell hybridoma specific for OVA 257–264 (SIINFEKL) bound to
H-2K
 
b
 
 MHC class I molecules (32). 3A9 is a CD4
 
1
 
 T cell hybrid-
oma specific for the hen egg lysozyme determinant correspond-
ing to residues 46–61 bound to the MHC class II molecule I-A
 
k
 
(33).
 
HSP.
 
Recombinant HSP 70 protein was expressed from the
pMS236 plasmid constructed by cloning the 1.96-kb NcoI-XbaI
fragment of the genomic mouse clone hsp70.1 (34) into the
pTrc99 expression vector (Amersham Pharmacia Biotech). Ex-
pression in DH5
 
a
 
 cells was induced by 1 mM isopropyl-
 
b
 
-
 
d
 
-
thiogalactopyranoside (IPTG), harvested cells were disrupted,
and clarified supernatants were loaded onto a DEAE Sephacel
column (Amersham Pharmacia Biotech). Elution of HSP 70 was
achieved by applying a 25–500 mM NaCl gradient. Fractions
containing HSP 70 were loaded onto an ATP-agarose column
(Sigma-Aldrich), and elution was achieved by applying a 0–1
mM ATP gradient. Fractions containing HSP 70 were precipi-
tated with 80% ammonium sulfate, redissolved in low salt buffer
containing magnesium acetate, dialyzed against the same buffer,
and aliquots were stored at 
 
2
 
80
 
8
 
C. Bovine HSP 70 was pur-
chased from Sigma-Aldrich.
 
HSP/Antigen Complexes.
 
The loading of mouse HSP 70 was
performed as described previously (11) with minor variations.
The HSP and the hybrid peptide (synthesized by Bio-Synthesis,
Inc.) were incubated together in PBS containing 1 mM KCl, 2
mM MgCl
 
2
 
,
 
 
 
and 100 
 
m
 
M ATP for 45 min at room temperature.
1 mM ADP was added, and the incubation was extended for an
additional 30 min. The free hybrid peptide was removed by ex-
tensive washing using a Centricon 30K (Amicon), until the resid-
ual free hybrid peptide was calculated to be in the picomolar
range. The efficiency of the loading was determined with iodine-
labeled hybrid peptide to be 
 
z
 
20% in most preparations.
 
Bioassays. 
 
10
 
5
 
 thioglycollate-induced macrophages were cul-
tured overnight in each well of a flat-bottomed 96-well plate in
the absence or presence of the indicated antigens and 5 
 
3
 
 10
 
4
 
B3Z or 3A9 cells in a final volume of 200 
 
m
 
l. As an indication of
the T cell activation, IL-2 accumulation in the supernatant at 16 h
was measured by ELISA (BD PharMingen) (26). For the com-
petition experiments, macrophages were preincubated with the
indicated amount of unloaded bovine HSP 70 (Sigma-Aldrich)
for 30 min at 37
 
8
 
C in a final volume of 100 
 
m
 
l. Without washing,
loaded HSP 70 or antigenic peptide was then added along with
5 
 
3
 
 10
 
4
 
 B3Z cells, and incubation continued for an additional 16 h
before assay of IL-2 accumulation. Error bars show SEM; where
no bars are visible, the errors were too small to plot.
 
Lactacystin Treatment.
 
(C57BL/6 
 
3
 
 C3H)F1 macrophages
were cultured for 8 h with the indicated antigens in the presence
or absence of 25 
 
m
 
M lactacystin (Calbiochem). The APCs were
then fixed with 1% paraformaldehyde for 10 min at room tem-
perature, treated for 10 min with 0.1 M glycine, washed, and cul-
tured overnight with either B3Z or 3A9 T cell hybridoma cells.
IL-2 accumulation in the supernatant at 16 h was measured as an
indication of T cell activation.
 
Immunofluorescence Staining. 
 
Bovine HSP 70 (Sigma-Al-
drich), BSA (Sigma-Aldrich), and 25-D1.16 (an mAb specific for
the SIINFEL/K
 
b
 
 complex [see reference 41]) were biotinylated
using 
 
N
 
-hydroxy succinimide–biotin (Pierce Chemical Co.) ac-
cording to the manufacturer’s directions. FITC-OVA (Molecular
Probes) was used at a concentration of 200 
 
m
 
g/ml. Rabbit anti- 
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calnexin (StressGen Biotechnologies) and FITC-conjugated mouse
anti–rabbit antibodies (Jackson ImmunoResearch Laborato-
ries) were used at 5 
 
m
 
g/ml. Steptavidin–Texas red (Southern
Biotechnology Associates) was used at 2 
 
m
 
g/ml. Biotinylated 25-
D1.16 was used at 10 
 
m
 
g/ml. Details of intracellular staining ana-
lyzed by immunofluorescence confocal microscopy are given in
the legend to Fig. 3. Details of the surface staining and internal-
ization assay, analyzed by immunofluorescence confocal micros-
copy, are given in the legend to Fig. 4. In brief, 5 
 
3
 
 10
 
5
 
 thiogly-
collate-induced macrophages were grown overnight in 24-well
plates on poly-
 
l
 
-lysine (Sigma-Aldrich) coated coverslips. The
next day, the coverslips were washed to remove the nonadherent
cells and incubated with the indicated antigens in 250 
 
m
 
l of com-
plete medium. Cells were fixed with 1% paraformaldehyde (see
Fig. 3) or with 3% paraformaldehyde (see Fig. 4) followed by
quenching with 0.1 M glycine. Unless otherwise indicated, cells
were permeabilized with 0.1% Brij. In Fig. 4 A, cells were stained
with Streptavidin–Texas red without permeabilization. Cover-
slips were mounted with Fluorosave (Calbiochem). Digital im-
ages were acquired using a Leica LSCM, composed in Adobe
Photoshop
 
®
 
, and printed after formatting in ClarisDraw.
 
Saturation and Competition Binding Assays. 
 
For saturation
binding analysis, 5 
 
3
 
 10
 
5
 
 thioglycollate-induced macrophages
were incubated with increasing concentrations of either biotiny-
lated HSP 70 or biotinylated BSA for 45 min on ice, then
washed. For the binding competition assay, macrophages were
incubated first with the indicated amount of unlabeled HSP 70 or
BSA for 45 min on ice, and followed without washing by incuba-
tion with biotinylated HSP 70 for an additional 45 min. Cells
were washed two times and incubated with Streptavidin-PE
(Molecular Probes) and FITC-CD11b (BD PharMingen), then
washed again. Data were collected using a FACScan™ flow cy-
tometer (Becton Dickinson) after addition of propidium iodide
and analyzed using CELLQuest™ software (Becton Dickinson).
Gates were set for CD11b
 
1
 
, propidium iodide–negative cells, and
either flow histograms of HSP staining of CD11b
 
1
 
 cells staining
were generated (competition experiment), or mean fluorescence
values of HSP staining for this cell subpopulation were calculated
(saturation analysis).
 
Results
 
Differential Roles of the Proteasome and TAP in MHC Class
I Presentation of SIINFEKL Present in Two Distinct HSP
Complexes.
 
To gain a better understanding of HSP anti-
genicity, with its implications for both the basic biology of
antigen presentation and the development of HSP-based
vaccines, we first addressed whether the proposed “regurgi-
tation” route or the cytosol to ER route, or both, contrib-
utes to the presentation of HSP-associated antigen. This
was accomplished by examining the effects of inhibiting
proteasome activity or eliminating TAP function on T cell
stimulation by HSP/antigen complexes. Mouse HSP 70
was loaded
 
 
 
in vitro with synthetic antigens containing the
amino acid sequence SIINFEKL (residues 257–264 of
OVA) that is presented by H-2K
 
b
 
. The binding motif of
HSP 70 consists of a hydrophobic core of four to five
amino acids and two flanking regions enriched in basic res-
idues (8, 35). Because SIINFEKL does not contain this
motif, we synthesized hybrid peptides containing a se-
quence derived from BiP that binds avidly to HSP 70 and
that is connected to SIINFEKL via a GSG linker at the an-
tigenic peptide’s NH
 
2
 
 terminus (HWDFAWPWGSGSI-
INFEKL, referred to as BiP-OVA) or the converse (SIIN-
FEKLGSGHWDFAWPW, referred to as OVA-BiP). The
two different orientations of SIINFEKL and BiP motif
were tested because the sequence context of a MHC class
I–binding determinant within a protein has been shown to
affect its efficiency of presentation (36, 37). With both of
these hybrid peptides, the loading efficiency of HSP 70 was
typically 20%, versus only 1% occupancy using antigenic
peptides not optimized for HSP binding (11; and data not
shown). These HSP/hybrid peptide complexes are highly
effective at priming CTL responses in vivo
 
 
 
(38).
In the presence of macrophages as APCs, HSP 70 loaded
with either BiP-OVA (HSP/BiP-OVA) or OVA-BiP
(HSP/OVA-BiP) stimulated IL-2 secretion from the SIIN-
FEKL/K
 
b
 
-specific T cell hybridoma B3Z, whereas neither
hybrid peptide added alone to macrophages was effective
(Fig. 1). This excludes the possibility that activation
achieved using HSP/hybrid peptide complexes is mediated
by residual free peptide and suggests that an active cellular
process is necessary for generation of the SIINFEKL/K
 
b
 
ligand. HSP 70 itself, or HSP 70 mixed with hybrid pep-
tides under conditions that do not support stable complex
formation, was not immunogenic. Taking into account the
20% loading, the HSP/antigen complexes were as efficient
on a molar basis as the potent optimal-length free SIIN-
FEKL peptide, despite their requirement for additional
processing.
The role of proteasomal enzymes in the presentation of
SIINFEKL from the HSP 70/antigen complexes was ex-
amined by incubating peritoneal macrophages with either
of the HSP/hybrid peptide complexes in the presence of
the potent proteasomal inhibitor lactacystin (39). Only
stimulation by HSP/OVA-BiP, but not by HSP/BiP-
OVA, was substantially inhibited by lactacystin used at 25
 
m
 
M, a concentration that did not influence presentation of
free SIINFEKL peptide or of an endosomally processed de-
terminant of hen egg lysozyme that binds to MHC class II
molecules (Fig. 2 A). Such selective inhibition argues
against either a general toxic effect or a nonspecific inhibi-
Figure 1. Antigenic peptides
derived from material bound to
HSP 70 in vitro can be pre-
sented by MHC class I mole-
cules of normal macrophages.
C57BL/6 macrophages were
cultured overnight in (1) the ab-
sence of any antigen, (2) the
presence of 1 nM SIINFEKL
peptide, (3) 2 mg of unloaded
HSP 70, (4) 20 nM OVA-BiP,
(5) 2 mg HSP70/OVA-BiP, (6)
20 nM BiP-OVA, or (7) 2 mg
HSP 70/BiP-OVA complexes
and 5 3 104 B3Z. IL-2 accumu-
lation in the supernatant at 16 h was measured as an indication of T cell
activation. Comparable results were obtained in .10 similar experiments. 
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tion of cellular proteases, and suggests that HSP can use
two distinct intracellular processing pathways to deliver an-
tigenic peptides to MHC class I molecules, only one of
which involves proteasome activity. To further define these
pathways, we tested the role of TAP. TAP-deficient mac-
rophages express lower levels of MHC class I molecules at
the cell surface than wild-type cells, but this limitation can
be overcome by growing the cells at reduced temperature
in 
 
b
 
2-microglobulin (40). TAP
 
2/2
 
 macrophages were
therefore grown at 26
 
8
 
C for 24 h and transferred to 37
 
8
 
C
when incubation with the antigens and the T cells was
started. In agreement with the data obtained using lactacys-
tin, TAP-deficient macrophages showed greatly impaired
presentation of SIINFEKL from HSP/OVA-BiP but not
from HSP/BiP-OVA (Fig. 2 B).
 
Direct Visualization of the Sites of SIINFEKL-K
 
b
 
 Binding
in Cells Exposed to HSP/Antigen Complexes.
 
These func-
tional experiments suggest that HSP/OVA-BiP is preferen-
tially processed via the classical class I pathway and imply
that the HSP/ligand complex, or the ligand alone, is trans-
located into the cytosol after which proteasomal cleavage
and TAP transport contribute to MHC class I loading of
released peptide in the ER. In contrast, HSP/BiP-OVA
appears to be predominantly processed by a distinct path-
way. To visualize directly the site(s) of SIINFEKL-MHC
class I association after exposure of cells to HSP/antigen
complexes, macrophages were incubated with each of the
HSP complexes, and the cells were stained with 25-D1.16,
an mAb to SIINFEKL/K
 
b
 
 complexes (41). Compared with
cells exposed to HSP only (not shown), we could detect
SIINFEKL/K
 
b
 
 complexes with 25-D1.16 when macro-
phages were incubated with either of the HSP/antigen prep-
arations. In agreement with the implications of the antigen
presentation studies, the intracellular distribution of these
MHC class I/peptide complexes varied depending on the
antigen employed. With HSP/BiP-OVA, whose presenta-
tion is insensitive to proteasomal inhibition and is TAP in-
dependent, a vesicular staining predominates (Fig. 3 A). 25-
D1.16 staining (Fig. 3 C) partially colocalizes with OVA
internalized by fluid phase endocytosis (Fig. 3, D–E), indi-
cating that with this HSP/antigen combination, SIIN-
FEKL-loaded MHC class I molecules are found preferen-
tially in endosomes. In contrast, when macrophages are
pulsed with HSP/OVA-BiP, the staining of vesicular struc-
tures is infrequent (Fig. 3 B), and the 25-D1.16 staining
(Fig. 3 F) largely colocalizes with calnexin used to identify
the ER (Fig. 3, G and H). Together with the above data on
proteasome and TAP dependence of HSP/OVA-BiP pre-
sentation, these staining data support the existence of an
HSP-mediated pathway for the translocation of polypep-
tides into the cytosol, in agreement with a recent study in-
volving a lymphoma cell line (30).
These functional and morphologic results thus reveal
that two distinct routes of processing can lead to MHC
class I presentation of HSP-associated antigenic material,
and also suggest that which pathway is preferentially used
depends on the relationship of the class I binding sequence
to the surrounding peptide structure. Having a free
COOH-terminal anchor residue (BiP-OVA) seems to be
associated with effective processing by an endosomal route.
In contrast, having this key binding residue within an ex-
tended polypeptide chain (OVA-BiP) appears to require
proteasomal action for efficiently placing this amino acid at
the COOH terminus of the processed material (42, 43).
Additional peptide sequences will need to be tested to de-
termine if this is truly a general rule, which would have im-
portant implications for the design of HSP-based vaccines.
 
Possible Role of Receptor-mediated Uptake in HSP-dependent
Antigen Presentation.
 
The efficiency of presentation using
HSP/hybrid peptide complexes suggests the existence of a
specific mechanism that can maximize the available pool of
antigenic substrate within the cell. Several recent studies
have provided evidence for receptor-mediated binding of
various HSPs to cell surfaces (28) and/or receptor-medi-
ated uptake into endosomes (28, 29). To look for evidence
of a receptor uptake system under the conditions employed
Figure 2. Presentation of SIINFEKL from HSP/
OVA-BiP but not HSP/BiP-OVA is dependent on
proteasomal proteases and TAP. (A) The effect of
25 mM lactacystin on the presentation of the indi-
cated antigens to either the B3Z or the 3A9 T cell
hybridoma cells was assayed. In bars 1–7, the pre-
sentation to B3Z hybridoma cells was analyzed in
(1) the absence of any antigen, (2) the presence of 1
nM SIINFEKL peptide, (3) 10 nM SIINFEKL
peptide, (4) 20 nM OVA-BiP, (5) 2 mg HSP70/
OVA-BiP, (6) 20 nM BiP-OVA, or (7) 2 mg HSP
70/BiP-OVA complexes. In four independent ex-
periments, the presentation of HSP 70/BiP-OVA
was not affected by lactacystin, whereas the inhibi-
tion of the presentation of HSP70/OVA-BiP
ranged between 70 and 90%. The effect of lactacys-
tin on the presentation of HEL-46-61 to 3A9 hy-
bridoma cells was tested (8) in the absence of any
antigen, or (9) in the presence of 1 mg/ml hen egg
lysosyme. (B) 105 TAP-12/2 macrophages (C57BL/6 3 129) were grown at 268C for 24 h and transferred to 378C when incubation with the indicated
antigens and the T cells was started. The presentation to B3Z hybridoma cells was analyzed in (1) the absence of any antigen, (2) the presence of 1 nM
SIINFEKL peptide, (3) 10 nM SIINFEKL peptide, (4) 20 nM OVA-BiP, (5) 2 mg HSP70/OVA-BiP, (6) 20 nM BiP-OVA, or (7) 2 mg HSP 70/BiP-
OVA complexes. Similar results were obtained in three independent experiments. 
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here, we examined the interaction of biotinylated HSP
with peritoneal macrophages. Incubation with biotinylated
HSP 70 at 4
 
8
 
C resulted in binding to the cell surface (Fig. 4
A). The bound HSP was internalized into endocytic vesi-
cles when the cells were warmed to 37
 
8
 
C (Fig. 4 B), where
it partially colocalized with OVA provided as a fluid phase
marker (Fig. 4, C and D). This binding and rapid endocytic
uptake were specific to HSP 70, as biotinylated BSA gave
no surface staining at 4
 
8
 
C and little concentration in vesi-
cles after a longer time at 37
 
8
 
C under these conditions (not
shown). These data are in agreement with and extend re-
cent results showing that glucose-regulated protein (Grp)
96 and heat shock cognate protein (HSC) 70 can bind to
the plasma membrane and internalize into endosomal-like
structures (28, 29).
The surface binding observed microscopically could also
be detected using flow cytometry. Only 25–30% of isolated
peritoneal macrophages, a population composed largely of
the CD11b-brightest cells (data not shown), exhibited sub-
stantial cell surface binding of biotinylated HSP 70 (Fig. 4
E). Interestingly, this matches the proportion of HSP-
pulsed macrophages that can be lysed by CTLs specific for
HSP-associated antigen (12). Thus, the level of surface re-
ceptor expression correlates with and may determine effec-
tive presentation of HSP-associated ligand. Consistent with
the existence of a saturable, specific receptor system, surface
binding of biotinylated HSP to the CD11b
 
bright
 
 cells could
be partially but substantially inhibited by a 10-fold excess of
unlabeled HSP, but not by BSA (Fig. 4 E), and exposure to
increasing concentrations of HSP 70 resulted in staining
approaching a plateau at 200 
 
m
 
g/ml among the CD11b
 
bright
 
cells (Fig. 4 F). A 10-fold excess of unloaded HSP (100 
 
m
 
g/
ml) also substantially inhibited B3Z responses to either of
the HSP/hybrid peptide complexes (Fig. 4 G), in accord
with the idea that the receptor-mediated binding observed
by staining contributes to antigen presentation by both
processing pathways detailed above.
 
Discussion
 
The evidence provided here for both a cytosolic and en-
docytic route for MHC class I presentation of HSP-associ-
ated antigen provides new mechanistic insight into a well-
recognized functional property of HSP. The two pathways
we have directly visualized correspond to those previously
proposed to underlie presentation of material associated
with artificial particulate antigens or with bacteria (23–27).
In our own previous study of latex bead–associated protein,
the efficiency of MHC class I–dependent antigen presenta-
tion was low, which we considered inconsistent with the
operation of a highly evolved specific pathway (26). In
contrast, HSP-mediated antigen presentation is quite effi-
Figure 3. Direct visualization of two
distinct intracellular sites of SIINFEKL as-
sociation with MHC class I molecules af-
ter antigen delivery via HSP 70. C57BL/6
macrophages were incubated for 6 h at
378C with either 100 mg/ml of HSP/BiP-
OVA (A, C–E) or HSP/OVA-BiP (B,
F–H). During the last 30 min of incubation,
FITC-OVA was added to some of the
samples. A, B, C, and F show the red
channel fluorescence of cells stained with
biotinylated 25-D1.16 followed by
Streptavidin–Texas red. C shows the red
channel (SIINFEKL/Kb complexes) for
one cell, demonstrating the predominant
vesicular location of these complexes; D
shows the green channel (FITC-OVA) for
the same high-power field; and E shows
the colocalization of the two signals (yel-
low), indicating the endosomal nature of
at least a fraction of the SIINFEKL/Kb-
containing structures. In F–H, cells were
double stained with biotinylated 25-
D1.16 followed by Streptavidin–Texas
red as well as with rabbit anticalnexin fol-
lowed by FITC-conjugated anti–rabbit Ig.
F shows the red channel (SIINFEKL/Kb
complexes), revealing primarily reticular
cytoplasmic staining along with a few
stained vesicles. G shows the green chan-
nel (calnexin) for the same cell. Colocal-
ization of the two signals (yellow) is seen
in H, consistent with an ER location for
the bulk of the SIINFEKL/Kb complexes.1962 Two Pathways for HSP-dependent Antigen Presentation by MHC Class I
cient and our congruent microscopic and functional evi-
dence support the existence of a specific receptor uptake
system for HSP/antigen complexes, extending both mor-
phological data and extensive quantitative uptake data from
other recent studies (28, 29) by showing a functional rela-
tionship between such receptor-dependent surface binding
and HSP-dependent MHC class I antigen presentation.
Receptor-mediated uptake improves MHC class II anti-
gen presentation by up to four orders of magnitude (14–18).
The presumably similar enhancing effects of such uptake
on the HSP-dependent presentation pathway, together
with the expression of these putative receptors on subsets
of professional APCs involved in initiating immune re-
sponses (including splenic dendritic cells [Castellino, F.,
unpublished results]), strongly imply that class I, and possi-
bly also class II, MHC molecule presentation of HSP-asso-
ciated antigens is a physiologically relevant pathway. The
heterogeneity seen for HSP 70 binding to peritoneal
mononuclear cells suggests that expression of the HSP
binding structures is regulated during cellular differentia-
tion, whereas the continued small increment in staining
observed at very high HSP concentrations (.200 mg/ml;
our unpublished observations) raises the possibility that
more than one affinity class of receptor may exist. The
staining at very high HSP concentrations could reflect
weak cross-binding among the different receptors proposed
by Arnold-Schild et al. to mediate Grp 96 versus HSP 70
binding (28).
Antigen cross-presentation plays a key role in responses
to tumors and possibly to virally infected nonhematopoietic
cells, as well as in the establishment of peripheral tolerance
(44). The mechanism of antigen acquisition and the cells
involved in in vivo presentation in these circumstances are
poorly understood. Uptake of apoptotic cells by phagocytic
dendritic cells has been suggested as a key event (22), but
recent data favor the activation of dendritic cells by mate-
rial from necrotic cells (45), followed by efficient antigen
presentation of released material by MHC class I molecules
(22, 46). The loss of HSP/protein complexes from cells dy-
ing a necrotic death could be readily imagined to lead to
Figure 4. A subset of normal macrophages expresses a surface receptor for HSP 70
that mediates internalization into endosomes. (A) C57BL/6 macrophages were incu-
bated with 100 mg/ml of biotinylated HSP 70 for 30 min at 48C; (B–D) after incuba-
tion as in A, the excess HSP was washed away and the macrophages were incubated
for an additional 30 min at 378C in the presence of FITC-OVA. All the samples
were washed and then stained with Streptavidin–Texas red either without perme-
abilization (A), or after permeabilization with 0.1% Brij (B–D). B shows the red
channel (HSP 70), and C shows the green channel (FITC-OVA). D shows the partial colocalization of the two signals (yellow). (E) 3 3 105 mac-
rophages were incubated at 48C with 50 mg/ml of biotinylated BSA (gray histogram), with 50 mg/ml of biotinylated HSP 70 (thick solid line), or with
500 mg/ml of unlabeled HSP 70 for 30 min, followed without washing by addition of 50 mg/ml of biotinylated HSP 70 and incubation for an additional
30 min (thin solid line), or with 500 mg/ml of unlabeled BSA for 30 min, followed without washing by addition of 50 mg/ml of biotinylated HSP 70 and
incubation for an additional 30 min (dotted line). Cells were stained with FITC-anti-CD11b and streptavidin-PE. Only propidium iodide–negative
CD11b1 cells are shown. (F) 5 3 105 macrophages were incubated at 48C with increasing concentrations of biotinylated HSP 70 or biotinylated BSA.
Cells were washed and stained with FITC–anti-CD11b and Streptavidin-PE. Only propidium iodide–negative CD11b1 cells are included in the analysis.
The mean fluorescence of the CD11bbright subpopulation of macrophages that shows high binding to HSP 70 is plotted. (G) Macrophages were cultured
overnight in the presence or absence of the indicated antigens and 5 3 104 B3Z cells. Where indicated “competitor,” macrophages were preincubated
for 30 min with 2 or 20 mg of unloaded HSP 70 in 100 ml of medium, followed without washing by addition of 2 mg of antigen-loaded HSP or SIIN-
FEKL and B3Z cells. In four independent experiments, the inhibition of the presentation of either HSP70/OVA-BiP or HSP 70/BiP-OVA by 20 mg of
competitor averaged 50%.1963 Castellino et al.
antigen delivery via the processing pathways described
here, in agreement with the proposal of Melcher et al. (47).
Some antigen-associated HSP might also be released from
viable infected or transformed cells due to saturation of the
KDEL-retrieval pathway (48) after the HSP upregulation
that results from stress due to microbial invasion or the
poor oxygenation of growing tumors. In these cases, the
complexes could contribute to an “early warning” system
that promotes T cell activation by professional APCs that
have efficiently bound them through surface receptors and
converted them into peptide/MHC molecule ligands suit-
able for T cell recognition.
Finally, from a cell biology point of view, we are left
with trying to understand how HSP/antigen complexes or
the antigenic cargo of HSP molecules move across endoso-
mal or plasma membranes into the cytosol. The only de-
scribed pathway across such membranes for normal cellular
proteins is in the opposite direction and involves lysosomes
(49). Whether the same pathway can operate in reverse or
whether another transport pathway remains to be discov-
ered poses an intriguing question.
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